公开(公告)号：US11492351B2

公开(公告)日：2022-11-08

申请号：US17018738

申请日：2020-09-11

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D471/04 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D401/14 ,  C07D487/04 ,  C12N9/10

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.

公开(公告)号：US20210078994A1

公开(公告)日：2021-03-18

申请号：US16948312

申请日：2020-09-11

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D471/04 ,  C07D237/32 ,  C07D401/10 ,  C07D403/12 ,  C07D417/10 ,  C07D403/10 ,  C07D413/10 ,  C07D413/14

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20230137886A1

公开(公告)日：2023-05-04

申请号：US18071384

申请日：2022-11-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Aaron Craig Burns ,  Xiaolun Wang ,  Svitlana Kulyk ,  Anthony Ivetac

IPC: C07D487/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D403/04 ,  C07D487/08 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  C07D471/08 ,  C07D237/34

Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.

公开(公告)号：US20230077225A1

公开(公告)日：2023-03-09

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230054883A1

公开(公告)日：2023-02-23

申请号：US17942367

申请日：2022-09-12

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D471/04 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D401/14 ,  C07D487/04 ,  C12N9/10

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US11479551B2

公开(公告)日：2022-10-25

申请号：US16948312

申请日：2020-09-11

Applicant: Mirati Therapeutics, Inc.

Inventor： Thomas P. Bobinski ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  John Michael Ketcham ,  Aaron Craig Burns ,  John David Lawson ,  Svitlana Kulyk ,  Jon Kuehler ,  Anthony Ivetac

IPC: C07D471/04 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D403/12 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D487/04 ,  C12N9/10 ,  C07D401/14

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.

公开(公告)号：US20210188857A1

公开(公告)日：2021-06-24

申请号：US17127582

申请日：2020-12-18

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Aaron Craig Burns ,  Xiaolun Wang ,  Svitlana Kulyk ,  Anthony Ivetac

IPC: C07D487/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D403/04 ,  C07D237/34 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  C07D471/08 ,  C07D487/08

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US10647715B2

公开(公告)日：2020-05-12

申请号：US16412091

申请日：2019-05-14

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Matthew Arnold Marx ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  John Gaudino ,  Julia Haas ,  John Michael Ketcham ,  John David Lawson ,  Brad Newhouse ,  Spencer Pajk ,  Christopher Ronald Smith ,  Tony P. Tang

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240391882A1

公开(公告)日：2024-11-28

申请号：US18658666

申请日：2024-05-08

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Christopher Ronald Smith ,  John Michael Ketcham ,  Stephen Harwood ,  Aaron Craig Burns ,  John David Lawson ,  Kersti Caddell-Haatveit

IPC: C07D241/44 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/048 ,  C07D491/08 ,  C07D491/107 ,  C07D491/147 ,  C07D491/18 ,  C07D495/04 ,  C07D495/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/20 ,  C07D513/04

Abstract: Disclosed herein are substituted quinoxalines, methods for their preparation, and use thereof.

公开(公告)号：US11999753B2

公开(公告)日：2024-06-04

申请号：US17553224

申请日：2021-12-16

Applicant: Mirati Therapeutics, Inc.

Inventor： Xiaolun Wang ,  Anthony Ivetac ,  Svitlana Kulyk ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D471/04 ,  A61K31/519 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.